2019
DOI: 10.1016/j.ajog.2018.11.115
|View full text |Cite
|
Sign up to set email alerts
|

104: Metformin prevents preeclampsia in an obese mouse model of soluble FMS-like tyrosine kinase-1 induced pre-eclampsia

Abstract: We aim to assess the effect of standardized maternal anesthesia and surgery during pregnancy on the developing fetal brain in a rabbit model. Comparable to humans, the brain growth spurt in rabbits occurs in the perinatal period. STUDY DESIGN: 14 time-mated pregnant does (155 pups) underwent a laparotomy for 1.5h at day 28 of gestation (term¼31d). After induction with propofol, anesthesia was maintained with 4 vol-% sevoflurane for 2h. Maternal vital signs were continuously monitored (blood pressure, heart rat… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2020
2020
2021
2021

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(2 citation statements)
references
References 0 publications
0
2
0
Order By: Relevance
“…In an obese mouse model of sFlt-1-induced PE, MET (300 mg/kg/day) significantly lowered mean and systolic blood pressure and reduced sFlt-1 levels in obese mice overexpressing sFlt-1, indicating the potential of MET in preventing PE in obese women (Jelliffe et al, 2019).…”
Section: The Promotion Of the Angiogenic Status By Metforminmentioning
confidence: 91%
See 1 more Smart Citation
“…In an obese mouse model of sFlt-1-induced PE, MET (300 mg/kg/day) significantly lowered mean and systolic blood pressure and reduced sFlt-1 levels in obese mice overexpressing sFlt-1, indicating the potential of MET in preventing PE in obese women (Jelliffe et al, 2019).…”
Section: The Promotion Of the Angiogenic Status By Metforminmentioning
confidence: 91%
“…Recently, Brownfoot et al reported that a low-dose combination of MET and sulfasalazine reduced sFlt-1 and sENG secretion and, on the contrary, increased VEGF alpha expression in cytotrophoblast (MET: 200 μM; sulfasalazine: 200 μM) and placental explants (MET: 400 μM; sulfasalazine: 400 μM), providing a more effective treatment or prevention for PE compared to MET as a single agent ( Brownfoot et al, 2020 ). In an obese mouse model of sFlt-1–induced PE, MET (300 mg/kg/day) significantly lowered mean and systolic blood pressure and reduced sFlt-1 levels in obese mice overexpressing sFlt-1, indicating the potential of MET in preventing PE in obese women ( Jelliffe et al, 2019 ).…”
Section: Proposed Mechanisms By Which Metformin May Prevent and Cure mentioning
confidence: 99%